Paclitaxel coated devices (PCD) used in the treatment of peripheral arterial disease: update to previous MHRA guidance on use. Where indicated, PCD can be considered as a treatment option for both critical limb ischaemia (CLI) and intermittent claudicatio

Level IV evidence from the Broitish government in the most prominent debate on cardiovascular pharmacology of the last few years: Since December 2018, the paclitaxel coated devices have been scrutinised for safety . This week’s guidance exonerates them on the strength of last years data.